Priority 5 from the Multiple Sclerosis PSP
| UNCERTAINTY: Does early treatment with aggressive disease modifying drugs improve the prognosis for people with multiple sclerosis? (JLA PSP Priority 5) | |
|---|---|
| Overall ranking | 5 |
| JLA question ID | 0016/5 |
| Explanatory note | Existing relevant systematic reviews are not up-to-date |
| Evidence |
No evidence found |
| Systematic reviews that need extending or updating |
He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009882. DOI: 10.1002/14651858.CD009882.pub2. |
| Systematic reviews in preparation |
No evidence found |
| Ongoing controlled trials |
Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome D-Lay-MS NCT01817166 Dose-related effects of Vitamin D3 on immune responses in patients with clinically isolated syndrome CISAVID NCT01728922 |
| Health Research Classification System category | Neurological |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | No examples provided. This is an indicative uncertainty and several submissions were merged to form this one. |
| Submitted by | 2 patients ~ 3 carers ~ 4 clinicians |
| Outcomes to be measured | Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs. |
| PSP information | |
|---|---|
| PSP unique ID | 0016 |
| PSP name | Multiple Sclerosis |
| Total number of uncertainties identified by this PSP. | 82 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | July 2013 |